Valuation: Celsion Corporation

Market Cap 6.93M 6.19M 5.72M 5.18M 9.69M 658M 9.85M 68.8M 27.24M 345M 26.01M 25.45M 1.09B P/E 2026 *
-0.51x
P/E 2027 * -0.66x
Enterprise Value 6.93M 6.19M 5.72M 5.18M 9.69M 658M 9.85M 68.8M 27.24M 345M 26.01M 25.45M 1.09B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celsion Corporation

Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 53 2026-06-30
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.28%+2.41%+49.51%+157.55% 42.57B
Weighted average by Cap. +0.39%+2.73%+47.57%+158.58%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.92M -11.93M -10.82M -20.23M -1.37B -20.57M -144M -56.86M -720M -54.29M -53.14M -2.27B -18.55M -16.57M -15.3M -13.87M -25.95M -1.76B -26.38M -184M -72.92M -923M -69.62M -68.14M -2.91B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Celsion Corporation